HOUSTON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the ...
FibroBiologics, Inc. Announces Investor Webinar on Innovative Fibroblast-Based Cell Therapy Platform
FibroBiologics, Inc., a clinical-stage biotechnology company focused on developing therapies for chronic diseases through fibroblasts, announced an investor webinar scheduled for July 10, 2025, at ...
In a recent study published in Nature, researchers investigated the immune-fibroblast communication in human cardiac disease and mouse models. They found that interleukin 1 beta (IL-1β) signaling ...
Researchers often struggle to select which cells to utilize in their research and when to employ them. Cell lines, dissociated tumor cells, and primary cells all have their place in research. While ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results